IP-LAD

Last updated
IP-LAD
IP-LAD.svg
Clinical data
Other namesIPRLAD; IP-LAD; IPLAD; 6-Isopropyl-6-nor-LSD; 6-Isopropyl-6-nor-lysergic acid diethylamide
Routes of
administration 		Oral
Legal status
Legal status
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class A
Identifiers
  • (6aR,9R)-N,N-Diethyl-7-propan-2-yl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
Formula C22H29N3O
Molar mass 351.494 g·mol−1
3D model (JSmol)
  • CCN(CC)C(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C(C)C
  • InChI=1S/C22H29N3O/c1-5-24(6-2)22(26)16-10-18-17-8-7-9-19-21(17)15(12-23-19)11-20(18)25(13-16)14(3)4/h7-10,12,14,16,20,23H,5-6,11,13H2,1-4H3/t16-,20-/m1/s1
  • Key:GLNOSFGSNDKLOC-OXQOHEQNSA-N
   (verify)

IP-LAD, or IPLAD, also known as IPR-LAD or as 6-isopropyl-6-nor-LSD, is an analogue of lysergic acid diethylamide (LSD) developed by the team of David E. Nichols. [1] [2] In studies on mice, it was found to be approximately 40% the potency of LSD, compared to the 60% increase in potency seen with ETH-LAD, 2-fold potency increase of AL-LAD, and roughly equivalent potency of PRO-LAD. [2]

Contents

See also

References

  1. ↑ Nichols DE, Oberlender R, McKenna DJ (1991). "Stereochemical Aspects of Hallucinogenesis". In Watson RR (ed.). Biochemistry and Physiology of Substance Abuse. Vol. 3. Boca Raton, Fla.: CRC Press. pp. 1–39. ISBN   978-0-8493-4463-3. OCLC   26748320. TABLE 1 Effects of N-(6)-Alkyl Subtituents on LSD-Like Behavior and Serotonin Receptor Affinity in Rats [...]
  2. 1 2 Hoffman AJ, Nichols DE (September 1985). "Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives". Journal of Medicinal Chemistry. 28 (9): 1252–1255. doi:10.1021/jm00147a022. PMID   4032428.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.